Skip to main content
SpringerLink
Log in
Book cover

Clinical Ophthalmic Oncology pp 365–377Cite as

Intraocular Manifestations of Hematopoietic Disorders

  • Chapter
  • First Online:

Abstract

Disorders of the hematopoietic system span over a vast array of neoplastic and nonneoplastic conditions involving the blood and its components including bone marrow, hemoglobin, blood proteins, and blood cells such as erythrocytes, leukocytes, and thrombocytes at various stages of differentiation. The intraocular milieu may directly be affected by hematological malignancies in a number of ways, which include metastasis, hypercoagulable states, and microvascular ischemia. In addition, patients with hematopoietic neoplasms are often immunosuppressed, so that they tend to develop opportunistic ocular infections. It should be kept in mind that any type of side effects of the anticancer treatment can occur and mimic the signs of intraocular disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

    Article  CAS  PubMed  Google Scholar 

  2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  CAS  PubMed  Google Scholar 

  3. Notta F, Mullighan CG, Wang JCY, et al. Evolution of human BCR-ALB1 lymphoblastic leukemia-initiating cells. Nature. 2011;469:362–7.

    Article  CAS  PubMed  Google Scholar 

  4. Ng AP. Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms. Leuk Lymphoma. 2013;54:922–33.

    Article  CAS  PubMed  Google Scholar 

  5. Murati A, Brecqueville M, Devillier R, et al. Myeloid malignancies: mutations, models and management. BMC Cancer. 2012;12:304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Stone RM, O’Donnel MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004;2004:98–117.

    Article  Google Scholar 

  7. Basecke J, Podleschny M, Becker A, et al. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. Br J Haematol. 2008;141:52–9.

    Article  CAS  PubMed  Google Scholar 

  8. Kühnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int J Hematol. 2012;96:153–63.

    Article  PubMed  Google Scholar 

  9. Majeti R, Weissman IL. Human acute myelogenous leukemia stem cells revisited-there’s more than meets the eye. Cancer Cell. 2011;19:9–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Roboz GJ. Current treatment of acute myeloid leukemia. Curr Opin Oncol. 2012;24:711–9.

    Article  CAS  PubMed  Google Scholar 

  11. Alvarnas JC, Brown PA, Aoun P, et al. Acute lymphoblastic leukemia. J Natl Compr Cancer Netw. 2012;10:858–914.

    Article  CAS  Google Scholar 

  12. Loh ML, Mullighan CG. Advances in the genetics of high risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy. Clin Cancer Res. 2012;18(10):2754–67.

    Article  CAS  PubMed  Google Scholar 

  13. Blumenthal DT, Glenn MJ. Neurologic manifestations of hematologic disorders. Neurol Clin. 2002;20:265–81.

    Article  PubMed  Google Scholar 

  14. Martin A, Morgan E, Hijiya N. Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments. Paediatr Drugs. 2012;14:377–87.

    Article  PubMed  Google Scholar 

  15. Torgerson SR, Haddad RY, Atallah E. Chronic myelogeneous leukemia for primary care physicians. Dis Mon. 2012;58:168–76.

    Article  PubMed  Google Scholar 

  16. Melo JV, Barnes DJ. Chronic myeloid leukemia as a model for disease evolution in human cancers. Nat Rev Cancer. 2007;7:441–53.

    Article  CAS  PubMed  Google Scholar 

  17. Tanaka MF, Kantarjian H, Cortes J, et al. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother. 2012;13:815–28.

    Article  CAS  PubMed  Google Scholar 

  18. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371:1017–21.

    Article  CAS  PubMed  Google Scholar 

  19. Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107:742–51.

    Article  CAS  PubMed  Google Scholar 

  20. Brown JR, Levine RL, Thompson C, et al. Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia. 2008;22:1966–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Chen RS, Raval A, Johnson AJ, et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2009;106:13433–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Tedeschi A, Vismara E, Ricci F, et al. The spectrum of use of rituximab in chronic lymphocytic leukemia. Onco Targets Ther. 2010;3:227–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Komrokji RS, Zhang L, Bennet JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am. 2010;24:443–57.

    Article  PubMed  Google Scholar 

  24. Haferlach T. Molecular genetics in myelodysplastic syndromes. Leuk Res. 2012;36:1459–62.

    Article  CAS  PubMed  Google Scholar 

  25. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–8.

    Article  CAS  PubMed  Google Scholar 

  26. Kezuka T, Usui E, Suzuki E, et al. Ocular complications in myelodysplastic syndromes as preleukemic disorders. Jpn J Ophthalmol. 2005;49:377–83.

    Article  PubMed  Google Scholar 

  27. Lin YC, Liang TH, Chang HN, et al. Behçet disease associated with myelodysplastic syndrome. J Clin Rheumatol. 2008;14:169–74.

    Article  PubMed  Google Scholar 

  28. Loeffler KU, McLean IW. Bilateral necrotizing scleritis and blindness in the myelodysplastic syndrome presumably due to relapsing polychondritis. Acta Ophthalmol Scand. 2000;78:228–31.

    Article  CAS  PubMed  Google Scholar 

  29. Kincaid MC, Green WR. Ocular and orbital involvement in leukemia. Surv Ophthalmol. 1983;27(4):211–32.

    Article  CAS  PubMed  Google Scholar 

  30. Reddy SC, Jackson N, Menon BS. Ocular involvement in leukemia--a study of 288 cases. Ophthalmologica. 2003;217(6):441–5.

    Article  CAS  PubMed  Google Scholar 

  31. Buchan J, McKibbin M, Burton T. The prevalence of ocular disease in chronic lymphocytic leukaemia. Eye (Lond). 2003;17(1):27–30.

    Article  CAS  Google Scholar 

  32. Charif Chefchaouni M, Belmekki M, Hajji Z, et al. Manifestations ophtalmologiques des leucémies aiguës. J Fr Ophtalmol. 2002;25(1):62–6.

    CAS  PubMed  Google Scholar 

  33. Lang GE, Spraul CW, Lang GK. Okuläre Veränderungen bei hämatologischen Grunderkrankungen. Klin Monatsbl Augenheilkd. 1998;212(6):419–27.

    Article  CAS  PubMed  Google Scholar 

  34. Bitirgen G, Belviranli S, Caliskan U, et al. Ophthalmic manifestations in recently diagnosed childhood leukemia. Eur J Ophthalmol. 2016;26(1):88–91.

    Article  PubMed  Google Scholar 

  35. Eliassi-Rad B, Albert DM, Green WR. Frequency of ocular metastases in patients dying of cancer in eye bank populations. Br J Ophthalmol. 1996;80:125–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lin P, Mruthyunjaya P. Retinal manifestations of oncologic and hematologic conditions. Int Ophthalmol Clin. 2012;52:67–91.

    Article  PubMed  Google Scholar 

  37. Kinkaid MC, Green WR. Ocular and orbital involvement in leukemia. Surv Ophthalmol. 1983;27:211–32.

    Article  Google Scholar 

  38. Robb RM, Ervin LD, Sallan SE. A pathological study of eye involvement in acute leukemia of childhood. Trans Am Ophthalmol Soc. 1978;76:90–101.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Stucki A, Rivier AS, Gikic M, et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97:2121–9.

    Article  CAS  PubMed  Google Scholar 

  40. Brandao MM, Soares E, Salles TS, et al. Expression of inducible nitric oxide synthase is increased in acute myeloid leukemia. Acta Haematol. 2001;106:95–9.

    Article  CAS  PubMed  Google Scholar 

  41. Gordon KB. Ocular manifestations of leukemia. Ophthalmol Clin North Am. 1999;12:235–41.

    Article  Google Scholar 

  42. Sharma T, Grewal J, Gupta S, et al. Ophthalmic manifestations of acute leukemias. The ophthalmologist’s role. Eye. 2004;18:663–72.

    Article  CAS  PubMed  Google Scholar 

  43. Jackson N, Reddy SC, Harun MH, et al. Macular hemorrhage in adult acute leukaemia patients at presentation and the risk of subsequent intracranial hemorrhage. Br J Haematol. 1997;98:204–9.

    Article  CAS  PubMed  Google Scholar 

  44. Abu-el-Asrar AM, al-Momen AK, Kangave D, et al. Correlation of fundus lesions and hematologic findings in leukemic retinopathy. Eur J Ophthalmol. 1996;6:167–72.

    Article  CAS  PubMed  Google Scholar 

  45. Gordon KB, Rugo HS, Duncan JL, et al. Ocular manifestations of leukemia. Leukemic infiltration versus infectious process. Ophthalmology. 2001;108:2293–300.

    Article  CAS  PubMed  Google Scholar 

  46. Yoshida K, Hasegawa D, Takusagawa A, et al. Bullous exudative retinal detachment due to infiltration of leukemic cells in a child with acute lymphoblastic leukemia. Int J Hematol. 2010;92:535–7.

    Article  PubMed  Google Scholar 

  47. Chang GC, Moshfeghi DM, Alcorn DM. Choroidal infiltration in juvenile myelomonocytic leukaemia. Br J Ophthalmol. 2006;90:1067.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Soares MF, Braga FT, da Rocha AJ, et al. Optic nerve infiltration by acute lymphoblastic leukemia: MR contribution. Pediatr Radiol. 2005;37:799–802.

    Article  Google Scholar 

  49. Schocket LS, Massaro-Giordano M, Volpe NJ, et al. Bilateral optic nerve infiltration in central nervous system leukemia. Am J Ophthalmol. 2003;135:94–6.

    Article  PubMed  Google Scholar 

  50. Novakovic P, Kellie SJ, Taylor D. Childhood leukaemia: relapse in the anterior chamber of the eye. Br J Ophthalmol. 1989;73:354–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Hegde SP, Ursekar AT, Chitale AA. Relapsing acute myeloid leukemia presenting as hypopyon uveitis. Indian J Ophthalmol. 2011;59:391–3.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87:285–93.

    Article  PubMed  Google Scholar 

  53. Wautier MP, Heron E, Picot J, et al. Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion. J Thromb Haemost. 2011;9:1049–55.

    Article  CAS  PubMed  Google Scholar 

  54. Ahn BY, Choi KD, Choi YJ, et al. Isolated monocular visual loss as an initial manifestation of polycythemia vera. J Neurol Sci. 2007;258:151–3.

    Article  PubMed  Google Scholar 

  55. Mahendradas P, Shetty R, Avadhani K, et al. Polycythemia vera and increased hemophilic factor VIII causing acute zonal occult outer retinopathy: case report. Ocul Immunol Inflamm. 2010;18:319–21.

    Article  PubMed  Google Scholar 

  56. Rue KS, Hirsch LK, Sadun AA. Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera. Clin Ophthalmol. 2012;6:1763–5.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Parija S, Mohapatra MM, Pattnaik BK. Polycythemia vera presenting with bilateral papilledema: a rare case report. Indian J Ophthalmol. 2008;56:327–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Passamonti F. How I, treat polycythemia vera. Blood. 2012;120:275–84.

    Article  CAS  PubMed  Google Scholar 

  59. Beer PA. The pathogenesis of essential thrombocythemia. Curr Opin Hematol. 2011;18:323–9.

    Article  CAS  PubMed  Google Scholar 

  60. Imasawa M, Iijima H. Multiple retinal vein occlusions in essential thrombocythemia. Am J Ophthalmol. 2002;133:152–5.

    Article  PubMed  Google Scholar 

  61. Riemens A, te Boome L, Imhof S, et al. Current insights into ocular graft-versus-host disease. Curr Opin Ophthalmol. 2010;21:485–94.

    Article  PubMed  Google Scholar 

  62. Hessen M, Akpek EK. Ocular graft-versus-host disease. Curr Opin Allergy Clin Immunol. 2012;12:540–7.

    Article  CAS  PubMed  Google Scholar 

  63. Perez RL, Perez-Simon JA, Caballero-Velazquez T, et al. Limbus damage in ocular graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17:270–3.

    Article  PubMed  Google Scholar 

  64. Taylor CW, Taylor RE, Kinsey SE. Leukemic infiltration of the orbit: report of three cases and literature review. Pediatr Hematol Oncol. 2005;22:415–22.

    Article  CAS  PubMed  Google Scholar 

  65. Finger PT, Pro MJ, Schneider S, et al. Visual recovery after radiation therapy for bilateral subfoveal acute myelogenous leukemia (AML). Am J Ophthalmol. 2004;138:659–62.

    Article  PubMed  Google Scholar 

  66. Lee MH, Park MY, Lee JW. Leukemic glaucoma in a patient with chronic myeloid leukemia treated by intracameral methotrexate. Jpn J Ophthalmol. 2010;54:362–4.

    Article  PubMed  Google Scholar 

  67. Stewart MW, Gitter KA, Cohen G. Prognostic importance of ophthalmic manifestations in childhood leukemia. Br J Ophthalmol. 1992;76:651–5.

    Article  Google Scholar 

  68. Pournaras C. Pathologies vasculaires oculaires. Paris: Elsevier Mason; 2008. p. 499.

    Google Scholar 

  69. Fintelmann RE, Qian YE, Skalet A, et al. Anterior uveitis associated with high-dose cytosine arabinoside. Ocul Immunol Inflamm. 2010;18(6):485–7.

    Article  CAS  PubMed  Google Scholar 

  70. Georgalas I, Pavesio C, Ezra E. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imatinib mesylate: report of an unusual side effect. Graefes Arch Clin Exp Ophthalmol. 2007;245(10):1585–6.

    Article  PubMed  Google Scholar 

  71. Chacko JG, Behbehani R, Hundley KN, et al. Bortezomib-associated optic atrophy in two patients with multiple myeloma. J Neuroophthalmol. 2018;38(4):473–5.

    PubMed  Google Scholar 

  72. De Luca C, Shenouda-Awad N, Haskes C, et al. Imatinib mesylate (Gleevec) induced unilateral optic disc edema. Optom Vis Sci. 2012;89(10):e16–22.

    Article  Google Scholar 

  73. Govind Babu K, Attili VS, Bapsy PP, et al. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol. 2007;27(1):43–4.

    Article  CAS  PubMed  Google Scholar 

  74. Schmid KE, Kornek GV, Scheithauer W, et al. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51(1):19–40.

    Article  PubMed  Google Scholar 

  75. Mathew DJ, Arthur A, John SS. Presumed chemotherapy-induced optic neuropathy and maculopathy: a case report. Open Ophthalmol J. 2017;11:298–304.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Hilliard LM, Berkow RL, Watterson J, et al. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol. 1997;28(4):310–3.

    Article  CAS  PubMed  Google Scholar 

  77. Kalra R, Chavada B, Madhani NR, et al. Cyclophosphamide and/or anthracyclines induced epiphora in breast cancer patients: a rare side-effect. Curr Drug Saf. 2018;13(1):62–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ocular Oncology Service, Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey

    Bercin Tarlan & Hayyam Kiratli

Authors
  1. Bercin Tarlan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hayyam Kiratli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hayyam Kiratli .

Editor information

Editors and Affiliations

  1. University of Oxford, Oxford, UK

    Bertil E. Damato

  2. Cole Eye Institute Cleveland Clinic, Cleveland, OH, USA

    Arun D. Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tarlan, B., Kiratli, H. (2019). Intraocular Manifestations of Hematopoietic Disorders. In: Damato, B., Singh, A. (eds) Clinical Ophthalmic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-17879-6_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-17879-6_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-17878-9

  • Online ISBN: 978-3-030-17879-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation